Global Chronic Rhinosinusitis with Nasal Polyps Market Assessment, By Treatment Type [Medications, Surgical Methods], By Route of Administration [Nasal, Oral, Others], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies], By Region, Opportunities and Forecast, 2017-2031F
Global chronic rhinosinusitis with nasal polyps (CRSwNP) market is expected to experience rapid growth due to the growing prevalence of chronic rhinosinusitis with nasal polyps, ongoing clinical developments for addressing CRSwNP, and regulatory emphasis on the subject.
Home>Industry Reports>Global Chronic Rhinosinusitis with Nasal Polyps Market Assessment, Opportunities and Forecast, 2017-2031F
Chronic rhinosinusitis with nasal polyps (CRSwNP) market is projected to witness a CAGR of 6.33% during the forecast period 2024-2031, growing from USD 3.54 billion in 2023 to USD 5.78 billion in 2031F.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a condition characterized by persistent inflammation of the sinuses and the presence of benign inflammatory lesions called nasal polyps. These polyps typically develop in the ethmoid sinuses and can obstruct the nasal airways, leading to various symptoms such as facial pressure or pain, nasal congestion, hyposmia or anosmia (reduced or complete lack of smell), and postnasal drip.
The market is anticipated to grow under the influence of the growing prevalence of chronic rhinosinusitis which is anticipated to keep rising due to the increasing geriatric population, air pollution, excessive smoking, and many other reasons. The development of biologic therapies targeting specific inflammatory pathways for the treatment of chronic rhinosinusitis with nasal polyps and their regulatory approvals have significantly enhanced the growth of the market. The market is expected to grow due to the increasing awareness about disease and its available treatments. The market is expected to be driven by emerging drugs such as FASENRA (benralizumab), TEZSPIRE (tezepelumab), and Depemokimab/GSK3511294 among other factors. The development and manufacturing of proficient sinusitis drugs, despite the stringent approval process and time-consuming clinical trials are some of the major factors hampering the growth of the market.
In March 2023, Optinose announced that its supplemental new drug application (sNDA) for XHANCE has been accepted for review by the US FDA. XHANCE is a drug-device combination product that utilizes the Exhalation Delivery System (EDS) to deliver fluticasone propionate, a widely used nasal anti-inflammatory drug, high and deep into difficult-to-access sinuses and sinonasal drainage tracts. The sNDA submission is based on the results of two Phase 3 clinical trials from the ReOpen Program, which studied the treatment of chronic sinusitis.
Growing Prevalence of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
The prevalence of CRSwNP is consistently increasing. The disease burden is particularly high in patients with comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD) and in patients who need repeated treatment with systemic corticosteroids and/or surgery. Symptoms in CRSwNP patients include rhinorrhea, nasal congestion, and loss of smell. These symptoms impair both physical and mental health, including the quality of sleep. Targeted treatment of nasal polyps and the underlying processes of chronic sinus inflammation are medically necessary. Novel, well-tolerated therapies that provide effective symptom control minimize recurrence rates of nasal polyps being promoted and marketed by key players to cater to the requirements.
According to an article published in ‘Allergy, Asthma & Clinical Immunology’ journal in December 2023, chronic rhinosinusitis is estimated to affect about 2 to 14% of the United States population, out of which about 25 to 30% of cases are associated with the presence of nasal polyps (CRSwNP).
Clinical Developments for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic rhinosinusitis with nasal polyps (CRSwNP) is usually associated with asthma and allergic rhinitis. Diagnosis of CRSwNP is done by bilateral endoscopic visualization of polyps in the nasal area. Treatment options for CRSwNP include topical irrigation and intranasal corticosteroids, systemic corticosteroids, monoclonal antibodies, surgery, and biological therapies targeting underlying inflammatory processes. Additionally, targeting the underlying inflammatory pathways involved in the pathophysiology of CRSwNP, and offering new treatment options for patients with more severe or unresponsive diseases have been significant milestones for the treatment of CRSwNP. The role of biologics and corticosteroids in the market and advancements in these drug categories are anticipated to drive growth in the market. Various promising products in the clinical pipeline seem to contribute to the market expansion.
For instance, GSK’s Depemokimab (GSK3511294) is a pipeline drug that is expected to complete phase III clinical trials in the third quarter of the year 2024 and has shown significant efficacy in phase I and II clinical trials. Similarly, in January 2024, Upstream Bio announced the entry in phase II clinical trial and the beginning of dosing the first patients with Verekitug (UPB-101) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Dominance of Medications Segment
Medications are generally preferred over surgery for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), thus the segment dominates the market landscape. Medication allows for long-term management, helping to maintain remission and prevent recurrences. They minimize invasive procedures, especially when patients do not meet strict surgical requirements or if their symptoms remain controlled with pharmacotherapy. Medical treatment improves quality of life by allowing patients to manage their symptoms while avoiding complications associated with surgery. Medications are less expensive and easily available, and they are cost-effective options.
Although surgery may be required in several cases as medication dominates the market. The government initiatives to reduce the disease burden through subsidies and reimbursements might help in further expansion of the market.
For instance, in April 2023, Nucala became the first monoclonal antibody to be PBS-subsidized by the Australian government for the treatment of CRSwNP. Nucala is the product of GSK plc marketed since 2015. The initiative by the Australian government is anticipated to provide subsidized access to this new treatment option for CRSwNP patients.
Nasal Route of Administration to be the Leading Segment
The nasal route of administration is preferred for medications of chronic rhinosinusitis with nasal polyposis (CRSwNP) as it provides an easy and fast route for local treatment of nose and sinus diseases with lower doses than systemic administration and fewer adverse effects. For instance, intranasal corticosteroids, such as mometasone furoate nasal spray (MFNS), are the preferred treatment for CRSwNP. Other treatments that can be administered intranasally for CRSwNP include intranasal anticholinergic agents, intranasal cromones, and nasal saline. Several marketed products in the form of nasal inhalation and sprays are available for the treatment of CRSwNP. Expanding the scope of indication for already approved drugs for CRSwNP, promising a step of revenue generation for key players.
For instance, in January 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US Food and Drug Administration approved Dupixent (dupilumab) for the treatment of pediatric patients of age 1 to 11 years, and weight of at least 15 kg, suffering from eosinophilic esophagitis (EoE). Dupixent became the first medication approved in the United States specifically to treat these patients. The approval expands the approved indication of Dupixent including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, asthma, and EoE.
North America to be the Dominating Region
North America is anticipated to be the leading region in the market with a higher value share. The prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) in the United States is estimated to be around 2-14% as per various studies. The prevalence of CRSwNP is greater in men than in women. Asthma, allergy, and allergic rhinitis are the most common comorbidities associated with CRSwNP and the high occurrence of these conditions in North America increases the risk of CRSwNP. Obesity is one of the major risk factors for CRSwNP and more than 40% of the United States population is obese, further increasing the risk of CRSwNp.
Additionally, the strong presence of key market players in the region and the strong clinical pipeline for the treatment option for CRSwNP strengthens the lead position of North America. Regulatory emphasis on reducing the disease burden of CRSwNP is expected to expand the market.
For instance, in June 2023, the US Food and Drug Administration made its final industry guidelines titled "Developing Drugs for Treatment of Chronic Rhinosinusitis With Nasal Polyps" public. The guideline is intended to support sponsors in the creation of pharmaceuticals or biological products intended to treat nasal polyps and chronic rhinosinusitis (CRSwNP).
Future Market Scenario
· The major factor driving the future market scenario is the growing prevalence of chronic rhinosinusitis due to the rising aging population, pollution levels, and smoking tendencies of individuals. Aging and other comorbidities like asthma significantly increase the risk of disease occurrence.
· The development of medications for CRSwNP by exploring alternative inflammatory pathways such as interleukins 4, 5, 13, 33, ILC2 cells, and IgE along with other pathogenic mechanisms involved in CRS pathogenesis such as arachidonic acid pathway, extravascular fibrin deposition (coagulation cascade), and B-cell dysregulation, can open the market with newer and more effective drug candidates. For instance, Benralizumab is a promising drug candidate for AstraZeneca undergoing phase III clinical investigations which is expected to be completed in the early months of 2025.
Report Scope
“Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global chronic rhinosinusitis with nasal polyps (CRSwNP) market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031F |
|
Projected Growth Rate |
CAGR of 6.33% between 2024 and 2031F |
|
Revenue Forecast in 2031 |
USD 5.78 billion |
|
Units |
Revenue in USD billion |
|
Segments Covered |
Treatment Type, Route of Administration, Distribution Channel |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profile |
AstraZeneca plc, Amgen Inc, GlaxoSmithKline plc, Sanofi S.A., Regeneron Pharmaceuticals Inc, Optinose US Inc., Genentech USA, Inc., Novartis Pharmaceuticals Corporation, Medtronic plc (Intersect ENT, Inc.), Lyra Therapeutics, Inc. |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfill your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In the report, global chronic rhinosinusitis with nasal polyps (CRSwNP) market has been segmented into the following categories:
· By Treatment Type
o Medications
§ Corticosteroids
§ Biologics
□ Dupilumab (Dupixent)
□ Omalizumab (Xolair)
□ Mepolizumab (Nucala)
§ Antibiotics
§ Antifungal Drugs
o Surgical Methods
· By Route of Administration
o Nasal
o Oral
o Others
· By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East and Africa
Key Players Landscape and Outlook
Market players like Sanofi, Regeneron Pharmaceuticals, and GlaxoSmithKline have several promising products in the clinical pipeline which shows the market readiness of these companies. The regulatory approvals and expansion in approved indications for biologics are anticipated to divert the attention of key players for the development of further biologics and biosimilar products in the forecast years.
In January 2024, GSK plc and Aiolos Bio, Inc. announced an agreement under which GSK acquired Aiolos. Aiolos is a clinical-stage biopharmaceutical company focused on the unmet treatment needs of patients with specific respiratory and inflammatory conditions. The deal was valued at USD 1.4 billion. The acquisition enables GSK with access to Aiolos’ AIO-001, which is a long-acting anti-thymic stromal lymphopoietin monoclonal antibody prepared to enter phase 2 clinical trials for the treatment of adult asthma patients, with the potential for additional indications including chronic rhinosinusitis with nasal polyps.
Key Players Operating in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market are:
· AstraZeneca plc
· Amgen Inc
· GlaxoSmithKline plc
· Sanofi S.A.
· Regeneron Pharmaceuticals Inc
· Optinose US Inc.
· Genentech USA, Inc.
· Novartis Pharmaceuticals Corporation
· Medtronic plc (Intersect ENT, Inc.)
· Lyra Therapeutics, Inc.
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global chronic rhinosinusitis with nasal polyps (CRSwNP) market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. By Treatment Type
4.2.1.Medications
4.2.1.1. Corticosteroids
4.2.1.2. Biologics
4.2.1.2.1. Dupilumab (Dupixent)
4.2.1.2.2. Omalizumab (Xolair)
4.2.1.2.3. Mepolizumab (Nucala)
4.2.1.3. Antibiotics
4.2.1.4. Antifungal Drugs
4.2.2.Surgical Methods
4.3. By Route of Administration
4.3.1.Nasal
4.3.2.Oral
4.3.3.Others
4.4. By Distribution Channel
4.4.1.Hospital Pharmacies
4.4.2.Retail Pharmacies
4.4.3.Online Pharmacies
4.5. By Region
4.5.1. North America
4.5.2. Europe
4.5.3. Asia-Pacific
4.5.4. South America
4.5.5. Middle East and Africa
4.6. By Company Market Share (%), 2023
5. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Treatment Type
5.1.2.1. Medications
5.1.2.1.1. Corticosteroids
5.1.2.1.2. Biologics
5.1.2.1.2.1. Dupilumab (Dupixent)
5.1.2.1.2.2. Omalizumab (Xolair)
5.1.2.1.2.3. Mepolizumab (Nucala)
5.1.2.1.3. Antibiotics
5.1.2.1.4. Antifungal Drugs
5.1.2.2. Surgical Methods
5.1.3.By Route of Administration
5.1.3.1. Nasal
5.1.3.2. Oral
5.1.3.3. Others
5.1.4.By Distribution Channel
5.1.4.1. Hospital Pharmacies
5.1.4.2. Retail Pharmacies
5.1.4.3. Online Pharmacies
5.1.5.United States*
5.1.5.1. Market Size & Forecast
5.1.5.1.1. By Value
5.1.5.1.2. By Volume
5.1.5.2. By Treatment Type
5.1.5.2.1. Medications
5.1.5.2.1.1. Corticosteroids
5.1.5.2.1.2. Biologics
5.1.5.2.1.2.1. Dupilumab (Dupixent)
5.1.5.2.1.2.2. Omalizumab (Xolair)
5.1.5.2.1.2.3. Mepolizumab (Nucala)
5.1.5.2.1.3. Antibiotics
5.1.5.2.1.4. Antifungal Drugs
5.1.5.2.2. Surgical Methods
5.1.5.3. By Route of Administration
5.1.5.3.1. Nasal
5.1.5.3.2. Oral
5.1.5.3.3. Others
5.1.5.4. By Distribution Channel
5.1.5.4.1. Hospital Pharmacies
5.1.5.4.2. Retail Pharmacies
5.1.5.4.3. Online Pharmacies
5.1.6.Canada
5.1.7.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. Asia-Pacific
5.3.1.India
5.3.2.China
5.3.3.Japan
5.3.4.Australia
5.3.5.Vietnam
5.3.6.South Korea
5.3.7.Indonesia
5.3.8.Philippines
5.4. South America
5.4.1.Brazil
5.4.2.Argentina
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Treatment Type
6.2. By Route of Administration
6.3. By Distribution Channel
6.4. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.4.7. Supplier Power
7.4.8. Buyer Power
7.4.9. Substitution Threat
7.4.10. Threat from New Entrant
7.4.11. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. AstraZeneca plc
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Amgen Inc
13.3. GlaxoSmithKline plc
13.4. Sanofi S.A.
13.5. Regeneron Pharmaceuticals Inc
13.6. Optinose US Inc.
13.7. Genentech USA, Inc.
13.8. Novartis Pharmaceuticals Corporation
13.9. Medtronic plc (Intersect ENT, Inc.)
13.10. Lyra Therapeutics, Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 3. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 4. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 5. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 6. Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Region, 2017-2031F
Figure 7. North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 9. North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 10. North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 11. North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 12. North America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
Figure 13. United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 15. United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 16. United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 17. United States Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 18. Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 20. Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 21. Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 22. Canada Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 23. Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 25. Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 26. Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 27. Mexico Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 28. Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 30. Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 31. Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
Figure 34. Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 36. Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 37. Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Germany Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 40. France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 41. France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 42. France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 43. France Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 44. Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 46. Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 47. Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 48. Italy Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 49. United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 51. United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 52. United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 53. United Kingdom Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 54. Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 56. Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 57. Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 58. Russia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 59. Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 61. Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 62. Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 63. Netherlands Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 66. Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 67. Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 68. Spain Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 69. Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 71. Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 72. Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 73. Turkey Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 74. Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 76. Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 77. Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 78. Poland Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 79. South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 81. South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 82. South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 83. South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 84. South America Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 87. Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 88. Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 89. Brazil Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 90. Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 92. Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 93. Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 94. Argentina Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 95. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 97. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 98. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 99. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. Asia-Pacific Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
Figure 101. India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 102. India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 103. India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 104. India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 105. India Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 106. China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 107. China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 108. China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 109. China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 110. China Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 111. Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 113. Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 114. Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 115. Japan Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 118. Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 119. Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 120. Australia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 121. Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 123. Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 124. Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 125. Vietnam Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 128. South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 129. South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 130. South Korea Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 131. Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 133. Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 134. Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 135. Indonesia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 136. Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 138. Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 139. Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 140. Philippines Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 141. Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 143. Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 144. Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 145. Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 146. Middle East & Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 149. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 150. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 151. Saudi Arabia Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 152. UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 154. UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 155. UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 156. UAE Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 157. South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, By Volume, in Million Units, 2017-2031F
Figure 159. South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Treatment Type, 2017-2031F
Figure 160. South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Route of Administration, 2017-2031F
Figure 161. South Africa Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What are the regions covered in the final report of global chronic rhinosinusitis with nasal polyps (CRSwNP) market?
What are the major drivers influencing the growth of global chronic rhinosinusitis with nasal polyps (CRSwNP) market?
Who are the key players operating in global chronic rhinosinusitis with nasal polyps (CRSwNP) market?
What is the market size and growth rate of global chronic rhinosinusitis with nasal polyps (CRSwNP) market?
See Related Reports
Global Bone Densitometers Market Assessment, Opportunities and Forecast, 2017-2031F
There is an increased demand for dual-energy x-ray absorptiometry (DXA) in the global bone densitometers market. Also, increasing prevalence of osteoporosis, growing geriatric population, technological advancements, and collaborative research and new....Read More
Published on
May 2024
4,500
Global Medical Terminology Software Market Assessment, Opportunities and Forecast, 2017-2031F
Global medical terminology software market is expected to witness significant growth over the forecast period owing to an increase in measures for reducing clinical errors and rising investments towards the development of technologically advanced sol....Read More
Published on
May 2024
4,500
Global Legionella Testing Market Assessment, Opportunities and Forecast, 2017-2031F
Global legionella testing market will witness significant growth owing to the rapid expansion of the healthcare sector, increasing awareness about the importance of regular legionella testing, and rising prevalence of legionella related illnesses.....Read More
Published on
May 2024
4,500
Global Endoluminal Suturing Devices Market Assessment, Opportunities and Forecast, 2017-2031F
Global endoluminal suturing devices market is expected to witness significant growth over the forecast period owing to rise in the number of cases of gastrointestinal cancer and increasing preference for non-invasive procedures.....Read More
Published on
May 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
